<?xml version="1.0" encoding="UTF-8"?>
<p>Breast cancer is the most common noncutaneous malignant neoplasm,
 <sup>
  <xref rid="zoi201035r1" ref-type="bibr">1</xref>
 </sup> the management of which has traditionally used a triple-modality approach in the form of surgery after adjuvant chemotherapy and radiotherapy. Randomized clinical evidence of therapeutic equivalence between neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy led to significant changes in clinical practice.
 <sup>
  <xref rid="zoi201035r2" ref-type="bibr">2</xref>,
  <xref rid="zoi201035r3" ref-type="bibr">3</xref>,
  <xref rid="zoi201035r4" ref-type="bibr">4</xref>
 </sup> Neoadjuvant chemotherapy (ie, systemic therapy administered before surgery) allows for real-time response assessment and can downstage breast cancer, reducing the extent of local excision.
 <sup>
  <xref rid="zoi201035r5" ref-type="bibr">5</xref>
 </sup>
</p>
